Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

[1]  A. Płotka,et al.  The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers , 2014, Journal of acquired immune deficiency syndromes.

[2]  J. Drenth,et al.  Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. , 2013, The Journal of antimicrobial chemotherapy.

[3]  V. Garg,et al.  Review of Drug Interactions with Telaprevir and Antiretrovirals , 2013, Antiviral therapy.

[4]  G. Klintmalm,et al.  Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  J. Butterton,et al.  463 PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS , 2013 .

[6]  M. Buti,et al.  Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. , 2013, Journal of hepatology.

[7]  E. O'Mara,et al.  Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin , 2013, Antimicrobial Agents and Chemotherapy.

[8]  V. Garg,et al.  Pharmacokinetic Interaction between Telaprevir and Methadone , 2013, Antimicrobial Agents and Chemotherapy.

[9]  E. O'Mara,et al.  Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  V. Garg,et al.  The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers , 2013, British journal of clinical pharmacology.

[11]  M. Blonk,et al.  Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Lane R. Bushman,et al.  Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers , 2013, Journal of acquired immune deficiency syndromes.

[13]  Agnes Cha,et al.  Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. , 2012, American Journal of Health-System Pharmacy.

[14]  C. Quereda,et al.  Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. , 2012, Journal of acquired immune deficiency syndromes.

[15]  Samir K. Gupta,et al.  Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers , 2012, Hepatology.

[16]  Jörg Huwyler,et al.  Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. , 2012, Biochemical pharmacology.

[17]  V. Garg,et al.  The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir , 2012, Journal of clinical pharmacology.

[18]  V. Garg,et al.  Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin , 2012, Journal of clinical pharmacology.

[19]  V. Garg,et al.  Telaprevir: Pharmacokinetics and Drug Interactions , 2012, Antiviral therapy.

[20]  D. Samuel,et al.  Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence , 2012, Antimicrobial Agents and Chemotherapy.

[21]  N. Terrault,et al.  Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies , 2012, Current opinion in organ transplantation.

[22]  M. Nolan.  EMA approved new drugs: telaprevir and boceprevir , 2012 .

[23]  V. Garg,et al.  Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy , 2012, Antimicrobial Agents and Chemotherapy.

[24]  G. Everson,et al.  Review and management of drug interactions with boceprevir and telaprevir , 2012, Hepatology.

[25]  R. Fontana,et al.  Managing drug‐drug interactions with boceprevir and telaprevir , 2012, Clinical liver disease.

[26]  E. Greanya,et al.  A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. , 2012, Annals of hepatology.

[27]  L. Piroth.  Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. , 2011, Clinics and research in hepatology and gastroenterology.

[28]  K. Seden,et al.  Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. , 2011, Current opinion in HIV and AIDS.

[29]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[30]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[31]  V. Garg,et al.  Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin , 2011, Antimicrobial Agents and Chemotherapy.

[32]  V. Garg,et al.  Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus , 2011, Hepatology.

[33]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[34]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[35]  Région de la Capitale Nationale,et al.  Merck Canada Inc. , 2011 .

[36]  W. Tong,et al.  Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor , 2011, Drug Metabolism and Disposition.

[37]  J. Albrecht,et al.  12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY , 2011 .

[38]  M. Manns,et al.  Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.

[39]  S. Vinzio,et al.  Mécanismes des interactions médicamenteuses d’origine pharmacocinétique , 2010 .

[40]  L. Benet,et al.  Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite , 2009, Clinical pharmacology and therapeutics.

[41]  A. Treiber,et al.  Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.

[42]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[43]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[44]  K. Brøsen,et al.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.

[45]  Robert M Califf,et al.  What clinicians should know about the QT interval. , 2003, JAMA.

[46]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[47]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[48]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[49]  R. Bendayan,et al.  The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. , 2010, Trends in pharmacological sciences.

[50]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.